Study That Will Evaluate the Brazilian Population With COPD.

Recruiting now

Conditions studied: COPD (Chronic Obstructive Pulmonary Disease)

In brief

Observational, prospective, multicenter cohort study with consecutive inclusion of COPD patients. Eligible patients will be those with severe and very severe COPD according to the GOLD 2024 (Global Initiative for Chronic Obstructive Lung Disease) guidelines being followed at participating hospitals. The severity of COPD is related to the exacerbation rate, which in turn is related to the progression of the disease and the occurrence of complications and death. There is no national data on this subgroup.

Key facts

Study ID: NCT06780046
Run by: AstraZeneca
People needed: 693
Starts: 2025-01-31
Expected to finish: 2027-09-30
Last updated by the study team: 2026-07-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients of both sexes, aged 18 years or older, with confirmed COPD according to GOLD 2024: previous or current exposure and spirometry (FEV1/FVC =2 or CAT >=10); or
GOLD E (>=2 moderate or 1 severe exacerbation - hospitalization); or
GOLD 3 and 4 (FEV1 <50%).

You may not qualify if…

Advanced fibrosing interstitial lung disease (extent >=50%); and/or
High-risk pulmonary hypertension (on triple therapy); and/or
Active cancer - on systemic therapy

Where it is running

Research Site — São Paulo, Brazil (enrolling)
Research Site — Aparecida de Goiânia, Brazil (enrolling)
Research Site — Belém, Brazil (enrolling)
Research Site — Brasília, Brazil (enrolling)
Research Site — Campo Grande, Brazil (enrolling)
Research Site — Bahia, Brazil (enrolling)
Research Site — Goiânia, Brazil (enrolling)
Research Site — Santo André, Brazil (enrolling)
Research Site — Uberlândia, Brazil
Research Site — Florianópolis, Brazil

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.